Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

This trial is testing a combination of two treatments — a gene therapy virus (recombinant adenovirus type 5) injected into the tumor and a chemotherapy infusion delivered directly into the liver arteries (HAIC-FOLFOX) — for people with intrahepatic cholangiocarcinoma, a type of liver bile duct cancer that cannot be surgically removed. The virus is designed to selectively infect and kill cancer cells while boosting immune attack on the tumor. **You may be eligible if...** - You are 18 or older with biopsy-confirmed bile duct cancer inside the liver (intrahepatic mass-forming cholangiocarcinoma) - Your cancer cannot be surgically removed, or you decline surgery - Your cancer has at least one measurable lesion on scans - You have at least 3 months life expectancy - Your organ function (liver, kidneys, blood counts, heart) meets study requirements - You are willing to use contraception if applicable **You may NOT be eligible if...** - Your cancer has spread to areas that make liver-directed treatment ineffective - Your liver function is too poor (e.g., advanced liver failure) - You have a condition that is a contraindication to adenovirus infusion - You have had another anti-cancer treatment within the past 21 days - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.